当前位置: 首页 >> 检索结果
921. A randomized, controlled trial of maintenance interferon therapy for patients with chronic hepatitis C virus and persistent viremia.
作者: M L Shiffman.;C M Hofmann.;M J Contos.;V A Luketic.;A J Sanyal.;R K Sterling.;A Ferreira-Gonzalez.;A S Mills.;C Garret.
来源: Gastroenterology. 1999年117卷5期1164-72页
: At least half of patients with chronic hepatitis C virus (HCV) fail to respond to interferon or interferon/ribavirin therapy. Histological improvement is observed in some nonresponders. We conducted a randomized, controlled trial to determine if maintenance interferon therapy could prevent histological progression in this subset of nonresponders.
922. Oral budesonide and ursodeoxycholic acid for treatment of primary biliary cirrhosis: results of a prospective double-blind trial.
作者: M Leuschner.;K P Maier.;J Schlichting.;S Strahl.;G Herrmann.;H H Dahm.;H Ackermann.;J Happ.;U Leuschner.
来源: Gastroenterology. 1999年117卷4期918-25页
Ursodeoxycholic acid (UDCA) is used for treatment of primary biliary cirrhosis. Previous studies showed that, compared with UDCA monotherapy, bile salts plus prednisolone had no further effect on laboratory data but improved liver histology. Thirty percent of these patients had prednisolone-related side effects. Budesonide is a glucocorticoid with a high receptor affinity and a high first-pass metabolism. In this study we investigated whether budesonide and UDCA are superior to UDCA monotherapy.
923. Antibiotic efficacy in small intestinal bacterial overgrowth-related chronic diarrhea: a crossover, randomized trial.
作者: A Attar.;B Flourié.;J C Rambaud.;C Franchisseur.;P Ruszniewski.;Y Bouhnik.
来源: Gastroenterology. 1999年117卷4期794-7页
No controlled trial has examined the clinical efficacy of antibiotics in small bowel bacterial overgrowth.
924. A randomized trial comparing the effect of rofecoxib, a cyclooxygenase 2-specific inhibitor, with that of ibuprofen on the gastroduodenal mucosa of patients with osteoarthritis. Rofecoxib Osteoarthritis Endoscopy Study Group.
作者: L Laine.;S Harper.;T Simon.;R Bath.;J Johanson.;H Schwartz.;S Stern.;H Quan.;J Bolognese.
来源: Gastroenterology. 1999年117卷4期776-83页
Prostaglandin production in the normal gastrointestinal tract, believed to be critical for mucosal integrity, is mediated by cyclooxygenase (COX)-1, whereas prostaglandin production at inflammatory sites seems to occur via induction of COX-2. We hypothesized that COX-2-specific inhibition with rofecoxib (25 mg once daily) in the treatment of patients with osteoarthritis would cause fewer gastroduodenal ulcers than an equally effective dose of ibuprofen (800 mg 3 times a day), a nonspecific COX inhibitor.
925. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease.
作者: P Rutgeerts.;G D'Haens.;S Targan.;E Vasiliauskas.;S B Hanauer.;D H Present.;L Mayer.;R A Van Hogezand.;T Braakman.;K L DeWoody.;T F Schaible.;S J Van Deventer.
来源: Gastroenterology. 1999年117卷4期761-9页
Infliximab, an anti-tumor necrosis factor monoclonal antibody, rapidly reduces signs and symptoms of active Crohn's disease. The aim of this study was to determine whether repeated infusions of infliximab would effectively and safely maintain the remitting benefit.
926. Lack of effect of intravenous administration on time to respond to azathioprine for steroid-treated Crohn's disease. North American Azathioprine Study Group.
作者: W J Sandborn.;W J Tremaine.;D C Wolf.;S R Targan.;C A Sninsky.;L R Sutherland.;S B Hanauer.;J W McDonald.;B G Feagan.;R N Fedorak.;K L Isaacs.;M G Pike.;D C Mays.;J J Lipsky.;S Gordon.;C S Kleoudis.;R H Murdock.
来源: Gastroenterology. 1999年117卷3期527-35页
Azathioprine is effective for Crohn's disease but acts slowly. A loading dose may decrease the time to response.
928. Interferon-ribavirin for chronic hepatitis C with and without cirrhosis: analysis of individual patient data of six controlled trials. Eurohep Study Group for Viral Hepatitis.
作者: S W Schalm.;O Weiland.;B E Hansen.;M Milella.;M Y Lai.;A Hollander.;P P Michielsen.;A Bellobuono.;L Chemello.;G Pastore.;D S Chen.;J T Brouwer.
来源: Gastroenterology. 1999年117卷2期408-13页
The aim of this study was to compare interferon (IFN)-ribavirin combination therapy with IFN monotherapy in chronic hepatitis C with particular focus on its efficacy in cirrhosis.
929. Low-dose methotrexate is ineffective in primary biliary cirrhosis: long-term results of a placebo-controlled trial.
作者: M T Hendrickse.;E Rigney.;M H Giaffer.;I Soomro.;D R Triger.;J C Underwood.;D Gleeson.
来源: Gastroenterology. 1999年117卷2期400-7页
New treatments for primary biliary cirrhosis (PBC) need to be evaluated. We conducted a single-center double-blind, randomized trial of methotrexate, 7.5 mg/wk (n = 30), vs. placebo (n = 30) for up to 6 years in PBC.
930. Lack of effect of acid suppression therapy on gastric atrophy. Nordic Gerd Study Group.
作者: L Lundell.;P Miettinen.;H E Myrvold.;S A Pedersen.;K Thor.;A Andersson.;J Hattlebakk.;N Havu.;E Janatuinen.;K Levander.;B Liedman.;P Nyström.
来源: Gastroenterology. 1999年117卷2期319-26页
A hypothesis suggesting that profound acid inhibition therapy facilitates and hastens the development of gastric glandular atrophy in patients infected with Helicobacter pylori was investigated in this randomized study comparing omeprazole therapy with antireflux surgery (ARS) for chronic gastroesophageal reflux disease (GERD).
931. Accuracy of polyp detection by gastroenterologists and nurse endoscopists during flexible sigmoidoscopy: a randomized trial.
作者: P Schoenfeld.;S Lipscomb.;J Crook.;J Dominguez.;J Butler.;L Holmes.;D Cruess.;D Rex.
来源: Gastroenterology. 1999年117卷2期312-8页
The use of nurse endoscopists to perform flexible sigmoidoscopy is expanding, increasing the availability of colorectal cancer screening. However, the effectiveness of this practice has not been studied in randomized trials. The aim of this trial was to examine the miss rate of polyps, the depth of sigmoidoscope insertion, and the incidence of complications during flexible sigmoidoscopy performed by nurse endoscopists and by gastroenterologists.
933. Preliminary evaluation of safety and activity of recombinant human interleukin 11 in patients with active Crohn's disease.
作者: B E Sands.;S Bank.;C A Sninsky.;M Robinson.;S Katz.;J W Singleton.;P B Miner.;M A Safdi.;S Galandiuk.;S B Hanauer.;G W Varilek.;A L Buchman.;V D Rodgers.;B Salzberg.;B Cai.;J Loewy.;M F DeBruin.;H Rogge.;M Shapiro.;U S Schwertschlag.
来源: Gastroenterology. 1999年117卷1期58-64页
Recombinant human interleukin 11 (rhIL-11) is a cytokine with thrombocytopoietic activity and anti-inflammatory and mucosal protective effects. The objectives of this study were to investigate the safety and tolerability of rhIL-11 in patients with Crohn's disease and to explore the effects of dose and schedule on platelet count and Crohn's disease activity.
934. Recombinant Norwalk virus-like particles given orally to volunteers: phase I study.
作者: J M Ball.;D Y Graham.;A R Opekun.;M A Gilger.;R A Guerrero.;M K Estes.
来源: Gastroenterology. 1999年117卷1期40-8页
Norwalk virus (NV) is a major cause of epidemic gastroenteritis. The NV capsid is composed of a single protein that forms recombinant (rNV) virus-like particles (VLPs). In mice, these VLPs are immunogenic when administered orally without adjuvant, and they elicit serum immunoglobulin (Ig) G and intestinal IgA responses. The aim of this study was to evaluate the safety and immunogenicity of rNV VLPs in healthy volunteers.
935. Effects of very low dose daily, long-term aspirin therapy on gastric, duodenal, and rectal prostaglandin levels and on mucosal injury in healthy humans.
The safety of low-dose daily aspirin therapy in the gastrointestinal tract is uncertain. Our objectives were to evaluate the long-term effects of very low daily aspirin doses in the gastrointestinal tract and effects on platelet-derived serum thromboxane levels in volunteers.
936. Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn's disease: A European multicenter trial.
作者: G D'haens.;S Van Deventer.;R Van Hogezand.;D Chalmers.;C Kothe.;F Baert.;T Braakman.;T Schaible.;K Geboes.;P Rutgeerts.
来源: Gastroenterology. 1999年116卷5期1029-34页
Tumor necrosis factor (TNF) is a pivotal cytokine in intestinal inflammation. Controlled trials using a chimeric anti-TNF antibody (infliximab) have shown its efficacy in refractory Crohn's disease.
937. Comparative effects of oxygen supplementation on theophylline and acetaminophen clearance in human cirrhosis.
Sinusoidal capillarization in cirrhosis may impair the transfer of oxygen into hepatocytes; this may contribute to impaired oxidative drug metabolism. The aim of this study was to test this hypothesis by comparing the effects of oxygen supplementation in cirrhotic patients on the clearance of theophylline, which is dependent on hepatic oxidative metabolism, with its effect on the clearance of acetaminophen, which is reliant on hepatic conjugation reactions.
938. Oral immunization with urease and Escherichia coli heat-labile enterotoxin is safe and immunogenic in Helicobacter pylori-infected adults.
作者: P Michetti.;C Kreiss.;K L Kotloff.;N Porta.;J L Blanco.;D Bachmann.;M Herranz.;P F Saldinger.;I Corthésy-Theulaz.;G Losonsky.;R Nichols.;J Simon.;M Stolte.;S Ackerman.;T P Monath.;A L Blum.
来源: Gastroenterology. 1999年116卷4期804-12页
Oral immunization with Helicobacter pylori urease can cure Helicobacter infection in animals. As a step toward therapeutic immunization in humans, the safety and immunogenicity of oral immunization with recombinant H. pylori urease were tested in H. pylori-infected adults.
939. Mesalamine in the treatment of mild to moderate active Crohn's ileitis: results of a randomized, multicenter trial.
作者: C Prantera.;M Cottone.;F Pallone.;V Annese.;A Franzè.;R Cerutti.;G Bianchi Porro.
来源: Gastroenterology. 1999年116卷3期521-6页
The efficacy of 5-aminosalicylic acid (mesalamine) in the treatment of flare-ups of Crohn's disease is controversial. In previous studies, different locations and pathological behavior of Crohn's disease could have obscured the efficacy of these drugs that deliver their substance in different intestinal sites. The present study tested two different mesalamine formulations with 6-methylprednisolone in mild to moderate active Crohn's ileitis.
940. Oral budesonide for prevention of postsurgical recurrence in Crohn's disease. The IOIBD Budesonide Study Group.
作者: G Hellers.;A Cortot.;D Jewell.;C E Leijonmarck.;R Löfberg.;H Malchow.;L G Nilsson.;F Pallone.;S Pena.;T Persson.;C Prantera.;P Rutgeerts.
来源: Gastroenterology. 1999年116卷2期294-300页
Prevention of postoperative recurrence after resection for Crohn's disease (CD) would be of great clinical benefit. The efficacy of oral budesonide for prevention of endoscopic recurrence was evaluated in patients undergoing resection for ileal or ileocecal CD.
|